Baseline characteristics of all 149 patients with indolent and aggressive lymphoma stratified by immunohistochemical expression of CD20 antigen
| . | Strong . | Reduced . | Negative . | Total . |
|---|---|---|---|---|
| (n = 131) . | (n = 13) . | (n = 5) . | (N = 149) . | |
| Sex, n (%) | ||||
| Female | 49 (37.4) | 8 (61.5) | 1 (20.0) | 58 (38.9) |
| Male | 82 (62.6) | 5 (38.5) | 4 (80.0) | 91 (61.1) |
| Age, y | ||||
| Median (range) | 71.1 (21.5-87.0) | 71.8 (52.0-79.3) | 72.1 (58.9-84.0) | 71.1 (21.5-87.0) |
| Treatment diagnosis, n (%) | ||||
| DLBCL | 84 (64.1) | 11 (84.6) | 5 (100) | 100 (67.1) |
| FL | 34 (26.0) | 2 (15.4) | 0 (0) | 36 (24.2) |
| Other | 13 (9.9) | 0 (0) | 0 (0) | 13 (8.7) |
| No. of previous lines of therapy, median (range) | 3.00 (0-9.00) | 2.00 (0-6.00) | 3.00 (1.00-4.00) | 2.00 (0-9.00) |
| ECOG performance status, median (range) | 0 (0-2.00) | 0 (0-1.00) | 1.00 (0-1.00) | 0 (0-2.00) |
| Ann Arbor stage, median (range) | 4.00 (1.00-4.00) | 3.00 (2.00-4.00) | 3.00 (3.00-4.00) | 4.00 (1.00-4.00) |
| Baseline lactate dehydrogenase, median (range), U/L | 233 (64.0-2500) | 312 (183-1390) | 210 (182-1340) | 245 (64.0-2500) |
| Previous autologous stem cell transplant, n (%) | 19 (14.5) | 4 (30.8) | 0 (0) | 23 (15.4) |
| . | Strong . | Reduced . | Negative . | Total . |
|---|---|---|---|---|
| (n = 131) . | (n = 13) . | (n = 5) . | (N = 149) . | |
| Sex, n (%) | ||||
| Female | 49 (37.4) | 8 (61.5) | 1 (20.0) | 58 (38.9) |
| Male | 82 (62.6) | 5 (38.5) | 4 (80.0) | 91 (61.1) |
| Age, y | ||||
| Median (range) | 71.1 (21.5-87.0) | 71.8 (52.0-79.3) | 72.1 (58.9-84.0) | 71.1 (21.5-87.0) |
| Treatment diagnosis, n (%) | ||||
| DLBCL | 84 (64.1) | 11 (84.6) | 5 (100) | 100 (67.1) |
| FL | 34 (26.0) | 2 (15.4) | 0 (0) | 36 (24.2) |
| Other | 13 (9.9) | 0 (0) | 0 (0) | 13 (8.7) |
| No. of previous lines of therapy, median (range) | 3.00 (0-9.00) | 2.00 (0-6.00) | 3.00 (1.00-4.00) | 2.00 (0-9.00) |
| ECOG performance status, median (range) | 0 (0-2.00) | 0 (0-1.00) | 1.00 (0-1.00) | 0 (0-2.00) |
| Ann Arbor stage, median (range) | 4.00 (1.00-4.00) | 3.00 (2.00-4.00) | 3.00 (3.00-4.00) | 4.00 (1.00-4.00) |
| Baseline lactate dehydrogenase, median (range), U/L | 233 (64.0-2500) | 312 (183-1390) | 210 (182-1340) | 245 (64.0-2500) |
| Previous autologous stem cell transplant, n (%) | 19 (14.5) | 4 (30.8) | 0 (0) | 23 (15.4) |
‘Other’ diagnoses includes mantle cell lymphoma, marginal zone lymphoma, small lymphocytic lymphoma, and chronic lymphoid leukemia.
DLBCL, diffuse large B-cell lymphoma; ECOG, Eastern Cooperative Oncology Group; FL, follicular lymphoma; IQR, interquartile range.